Drug Trial Radar · NCT02032524
Avalglucosidase Alfa Extension Study
Last checked: Nov 20, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Feb 27, 2014
Primary completion
Dec 12, 2022
Study completion Dec 12, 2022
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: Long-term safety and pharmacokinetics (PK) of avalglucosidase alfa Secondary Objective: Long-term effect of avalglucosidase alfa on pharmacodynamic variables
Conditions
- Glycogen Storage Disease Type II Pompe Disease
Interventions
Avalglucosidase AlfaDrug
Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Infusion Associated Reactions (IARs) and DeathsTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
- Number of Participants With Clinically Significant Physical Examination AbnormalitiesTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
- Number of Participants With Potentially Clinically Significant Abnormalities in BiochemistryTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
- Number of Participants With Potentially Clinically Significant Abnormalities in HematologyTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
- Change From Baseline in Urine BUN up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
- Change From Baseline in Urine Hyaline Casts up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
- Change From Baseline in Urine Leukocytes [White Blood Cell (WBC)] up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
- Change From Baseline in Urine Specific Gravity up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
- Change From Baseline in Urine pH up to Last IMP AdministrationTime frame: Baseline (Day 1) and last on-treatment values (up to 454 weeks)
- Number of Participants With Potentially Clinically Significant Vital Signs AbnormalitiesTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
- Number of Participants With Body Weight Increased/DecreasedTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
- Number of Participants With Potentially Clinically Significant 12-Lead Electrocardiogram (ECG) AbnormalitiesTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
- Number of Participants With Antidrug Antibodies (ADA) Status, Positive or NegativeTime frame: From first dose of IMP up to 4 weeks after the last treatment administration of the IMP, a maximum up to 458 weeks
- Maximum Observed Plasma Concentration (Cmax) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
- Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Real Time (AUClast) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
- Time Corresponding to the Last Concentration (Tlast) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
- Terminal Half-Life (t1/2z) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
- Apparent Total Body Clearance Steady-State (CLss) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
- Apparent Volume of Distribution Steady-State (Vss) of Avalglucosidase AlfaTime frame: Predose (prior to infusion), end of the infusion and at 1, 4, 8, 12, and 24 hours post-dose on Week 312
Locations
17 sites in 7 countries. Site status is shown where the registry gives one.
Investigational Site Number 840006
Phoenix, Arizona
Investigational Site Number 840010
Jacksonville, Florida
Investigational Site Number 840001
Kansas City, Kansas
Investigational Site Number 840008
St Louis, Missouri
Investigational Site Number 840002
Durham, North Carolina
Investigational Site Number 840011
Cincinnati, Ohio
Investigational Site Number 840009
Dallas, Texas
Investigational Site Number 840003
Fairfax, Virginia
Investigational Site Number 056001
Leuven, Belgium
Investigational Site Number 208001
København Ø, Denmark
Investigational Site Number 250003
Nice, France
Investigational Site Number 250002
Paris, France
Investigational Site Number 276003
Mainz, Germany
Investigational Site Number 276001
München, Germany
Investigational Site Number 276002
Münster, Germany
Investigational Site Number 528001
Rotterdam, Netherlands
Investigational Site Number 826003
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.